• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medigus prices $2m direct placement, releases Q3 earnings

Medigus prices $2m direct placement, releases Q3 earnings

November 27, 2017 By Fink Densford

Medigus

Medigus (TLV:MDGS) late last week priced a $1.6 million direct placement and released its third quarter earnings, seeing operating losses drop compared with the same period during the previous year.

In its direct placement, the company said it is offering 810,000 American depository shares at approximately $2 per ADS alongside unregistered warrants to purchase an additional 405,000 ADSs. The warrants in the direct placement have a term of 5.5 years and are exercisable at six months after the issuance date with an exercise price of $2.25 per ADS.

Medigus said it expects the offering to result in gross proceeds of approximately $1.6 million, which it intends to use for general corporate purposes, according to a press release.

The company expects the sale to close on or around November 28, subject to customary closing conditions.

In its financial release, the company reported revenues of $117,000 for the quarter, down 14% from the same quarter during the previous year, with operating loss of $1.3 million, down from $1.9 million during the same quarter in 2016.

Research & development costs were approximately $654,000, down 8%, while sales and marketing expenses clocked in at $159,000, down 54% from the same period last year. General administrative expenses were $490,000, down 51% compared with the previous year.

Medigus said that during the quarter, it expanded a distribution agreement with China’s Golden Grand and inked a distribution deal with Spain’s Izasa Hospital, who put in the first purchase order for its Muse system in October.

“In recent months, we have announced progress across key areas of our development strategy, including broadening the availability of our flagship Muse system with leading multinational distributors. We are positioned to enter 2018 with positive momentum as we drive our development and clinical programs forward,” CEO Chris Rowland said in a press release.

Shares in Medigus have risen 2.4% so far today, at $1.72 as of 1:25 p.m. EST.

Filed Under: Business/Financial News, MassDevice Earnings Roundup Tagged With: Medigus Ltd.

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy